Tisagenlecleucel

Immune Checkpoint Inhibitors Global Market Report 2022: Rising Prevalence of Cancer Boosts Sector Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 十二月 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Immune system, Large-cell lung carcinoma, Immunotherapy, PD-L1, Gardasil, Protein, Patient, Prevalence, Rituximab, Cancer, US, Tisagenlecleucel, Research, Lung cancer, American Cancer Society, Breast cancer, PD-1, Market share, Lymphoma, Death, Nivolumab, Skin cancer, Marketing, Region, Neoplasm, Pharmaceutical industry, Vaccine, Uranium

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer.

Key Points: 
  • Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer.
  • Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells.
  • Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others.
  • The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market.

EQS-News: First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

Retrieved on: 
星期五, 十二月 2, 2022
NYSE, Cell, Neoplasm, The 7 Habits of Highly Effective People, Sepsis, Survival, Lymphatic system, Skin, NVS, COGS, Safety, Human, Ministry, Probability, Weapon, Survival rate, Prognosis, Immune system, Cancer, Advertising, Immunotherapy, Annual report, Risk, MRK, Pfizer, Macrophage, Injection, FDA, Criticism of the Food and Drug Administration, Animal, Tisagenlecleucel, Marketing, Security (finance), Patient, Mortality, CAR, Pembrolizumab, Partnership, Merck, Merck & Co., Mouse, Food, Pharmaceutical industry, Vaccine, EU, Health, Phase

First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM

Key Points: 
  • First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM
    The issuer is solely responsible for the content of this announcement.
  • On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra.
  • Enlivexs lead drug candidate, AllocetraTM , was developed as an off-the-shelf cell therapy that reprograms macrophages , the immune cells responsible for killing infected or harmful cells in the body.
  • The next step for this new cell therapy is to test whether these promising preclinical results will translate to human studies.

Cryoport Reports Results for the Second Quarter 2022

Retrieved on: 
星期四, 八月 4, 2022
FDA, Reproductive medicine, U.S. Securities and Exchange Commission, Maas, Follicular lymphoma, Investor relations, Industry, Technology, Growth, SEC, Investment, Medicine, Bristol Myers Squibb, Security (finance), Annual report, Animal Health, Ology Bioservices, Marketing, COVID-19, Company, Program, Blas, Novartis, Tisagenlecleucel, BLA, EDT, Solution, Royal commission, European Commission, SEC filing, MAA, Gilead, Pharmaceutical industry, Video game, Renewable energy, Reinsurance, Review, EU

Biopharma/Pharma revenue increased to $51.7 million, up 14% or $6.2 million for the second quarter of 2022 compared to $45.5 million for the second quarter of 2021.

Key Points: 
  • Biopharma/Pharma revenue increased to $51.7 million, up 14% or $6.2 million for the second quarter of 2022 compared to $45.5 million for the second quarter of 2021.
  • Animal Health revenue increased to $9.6 million, up 14% or $1.2 million for the second quarter of 2022 compared to $8.4 million for the second quarter of 2021.
  • Reproductive Medicine revenue increased to $2.9 million, up 24% or $0.6 million for the second quarter of 2022 compared to $2.3 million for the second quarter of 2021.
  • IMPORTANT INFORMATION: A document titled "Cryoport Second Quarter 2022 In Review", providing a reviewofCryoport'srecentfinancialandoperationalperformanceandageneral businessupdate, will be issued at 4:05 p.m. EDT on Thursday, August 4, 2022.

$6.3 Billion Worldwide Cell Therapy Technologies Industry to 2031 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
星期四, 六月 23, 2022
Genetics, Health, Stem Cells, Benchmark, Population, Industry, Quality control, Medical Research Future Fund, Cardiovascular disease, B cell, Tissue, Government, CAR, Cancer, Pressure, Growth, CVD, Investment, MRFF, Stem cell, Create, Coronavirus, Asia-Pacific, Disorder, Cell, Muscle, Tisagenlecleucel, Marketing, Pharmaceutical industry

The cell therapy technologies market consists of sales of cell therapy technologies that are medicinal solutions used for developing and improving cell therapy, such as cell processing, cell banking, and point-of-care technologies.

Key Points: 
  • The cell therapy technologies market consists of sales of cell therapy technologies that are medicinal solutions used for developing and improving cell therapy, such as cell processing, cell banking, and point-of-care technologies.
  • Cell therapy is a type of treatment used to inject active cells into the body of a patient for treating some disorders.
  • Increasing investments by the government in cell-based research contributed to the growth of the global cell therapy technologies market.
  • Strategic collaborations and partnerships between the industry players are gaining popularity in the cell therapy technologies market.

$15 Bn CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insights, 2028 - ResearchAndMarkets.com

Retrieved on: 
星期三, 六月 15, 2022
Biotechnology, Health, Genetics, Stem Cells, Oncology, Time, Bayer, Lymphatic system, Cancer, Country, Central New York Regional Market, FDA, Approved, US, Technology, Mesothelioma, CAR, Company, Research, Human, Growth, Large-cell lung carcinoma, B-cell lymphoma, Adult, Patient, Blood, Neoplasm, Pharmaceutical industry, Vaccine, Axicabtagene ciloleucel, Tisagenlecleucel

The "Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Global CAR T cell therapy market opportunity is expected to surpass US$ 15 Billion by 2028.
  • Furthermore, heavy investments in clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.
  • Global & Regional Market Insight: Current & Market Forecast 2028
    CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
    6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR
    8.

Cell and Gene Therapy Global Market Report 2022 Featuring Gilead Sciences, Bristol-Myers Squibb, Novartis, Amgen, Merck, Organogenesis, Dendreon, Vericel, Bluebird Bio and Fibrocell Science - ResearchAndMarkets.com

Retrieved on: 
星期五, 五月 27, 2022
Biotechnology, Genetics, Health, Lymphoma, Multiple myeloma, Protest and strikes of the CGT union 2021, Genome, Medicine, Bristol Myers Squibb, Dermatology, Patient, Acute lymphoblastic leukemia, Novartis, COVID-19, Merck, Adult, Cell, Dendreon, Canadian Aviation Regulations, CGT, Gene, FDA, B-cell lymphoma, Hospital, Budget, Organization, Tisagenlecleucel, ALL, CAR, Amgen, Growth, Application, Gilead Sciences, Medical device, Pharmaceutical industry, Vaccine, Fine chemical

Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.

Key Points: 
  • Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.
  • The cell and gene therapy market consist of sales of cell and gene therapies by entities (organizations, sole traders and partnerships) that develop cell and gene therapies.
  • The main types of products in cell and gene therapy are cell therapy and gene therapy.
  • Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market.

Verismo Therapeutics Expands Scientific Team to Advance its KIR-CAR Platform for the Treatment of Solid Tumors

Retrieved on: 
星期二, 四月 19, 2022
UTC, Verismo, Temple University, MSAT, VP, Research, Center, Associate, Doctor of Philosophy, GMP, Patient, Clinical trial, Gene editing, Natural killer cell, Penn, Nature Medicine, Process, Technology, CAR, CMC, Technology transfer, University, Safety, Secondary research, Blood, Therapy, Immunology, Medical device, Pharmaceutical industry, Nature, IND, Medicine, Tisagenlecleucel, Microbiology

PHILADELPHIA, April 19, 2022 /PRNewswire/ -- Verismo Therapeutics, Inc., a recent Penn spin-out behind a novel naturally inducible multi-chain KIR-CAR platform technology for CAR T-cells, today announced the appointment of Dr. Jun Xu as Senior Director of Translational Science and Raymond Luke as Director of MSAT.

Key Points: 
  • "Their specialized backgrounds in immuno-oncology and manufacturing will serve as a strategic advantage as we advance towards our First-in-Human Clinical Trial for our KIR-CAR platform."
  • Prior to joining Verismo Therapeutics, Mr. Luke spent six years at Adaptimmune developing next generation cell therapies against solid tumor indications.
  • "I am honored to join Verismo and its team of world-class scientists on its mission to successfully treat solid tumors," said Raymond.
  • This continued function and persistence can lead to ongoing regression of solid tumors, including those refractory to traditional CAR T-cell therapies.

Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca's Scientific Advisory Board

Retrieved on: 
星期四, 四月 7, 2022
Therapy, Janssen, Pleasure, CTL019, Immunotherapy, Loyola University, Vaccine, Biotechnology, United States Air Force Scientific Advisory Board, Novartis, TCR, CEO, Fred Hutchinson Cancer Research Center, University, Loyola University Chicago, Eli Lilly, SAB, Pharmaceutical industry, Tisagenlecleucel

SDERTLJE, Sweden, April 7, 2022 /PRNewswire/ -- Anocca, a biotechnology company using its precisionbiology platforms to engineer a broad portfolio of innovative T cell therapeutics,today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB).

Key Points: 
  • SDERTLJE, Sweden, April 7, 2022 /PRNewswire/ -- Anocca, a biotechnology company using its precisionbiology platforms to engineer a broad portfolio of innovative T cell therapeutics,today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB).
  • Dr. Kalos is an internationally recognised expert in T cell immunotherapy with over 25 years' experience at the cutting edge of cell therapy, oncology vaccines, and immuno-oncology.
  • Michael was most recently Executive Vice President and Head of R&D at ArsenalBio, a next-generation cell therapy biotech in California.
  • Previously, Dr. Kalos led Immuno-oncology and Oncology Cell Therapies at Janssen and served as Chief Scientific Officer of Immuno-oncology at Eli Lilly.

Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca's Scientific Advisory Board

Retrieved on: 
星期四, 四月 7, 2022
Therapy, Janssen, Pleasure, CTL019, Immunotherapy, Loyola University, Vaccine, Biotechnology, United States Air Force Scientific Advisory Board, Novartis, TCR, CEO, Fred Hutchinson Cancer Research Center, University, Loyola University Chicago, Eli Lilly, SAB, Pharmaceutical industry, Tisagenlecleucel

SDERTLJE, Sweden, April 7, 2022 /PRNewswire/ -- Anocca, a biotechnology company using its precisionbiology platforms to engineer a broad portfolio of innovative T cell therapeutics,today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB).

Key Points: 
  • SDERTLJE, Sweden, April 7, 2022 /PRNewswire/ -- Anocca, a biotechnology company using its precisionbiology platforms to engineer a broad portfolio of innovative T cell therapeutics,today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB).
  • Dr. Kalos is an internationally recognised expert in T cell immunotherapy with over 25 years' experience at the cutting edge of cell therapy, oncology vaccines, and immuno-oncology.
  • Michael was most recently Executive Vice President and Head of R&D at ArsenalBio, a next-generation cell therapy biotech in California.
  • Previously, Dr. Kalos led Immuno-oncology and Oncology Cell Therapies at Janssen and served as Chief Scientific Officer of Immuno-oncology at Eli Lilly.

$3.68 Billion Worldwide Cellular Immunotherapy Industry to 2031 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
星期一, 三月 21, 2022
Pharmaceutical, Health, Oncology, Cell, Neoplasm, Growth, Acute leukemia, CAR, Research, Tisagenlecleucel, Cancer, TCR, Renal cell carcinoma, Skin cancer, Ovarian cancer, Brain, Immune system, TIL, Prostate cancer, Liver cancer, NK, Breast cancer, Lung cancer, Non-Hodgkin lymphoma, Patient, Mobile phone, Medical imaging

The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs.

Key Points: 
  • The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs.
  • The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, natural killer (NK) cell therapy.
  • Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period.
  • The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy.